Search

Displaying results 5951 - 5960 of 10000 in total
  1. Drug

    MaaT013

    go.drugbank.com/drugs/DB18648
    Investigational

    MaaT013 is an allogeneic fecal microbiota therapy. It is being investigated for the treatment of Graft-Versus-Host Disease.

  2. Drug

    EGS21

    go.drugbank.com/drugs/DB05056
    Experimental

    EGS21(TM) is a beta-D-glucosylceramide (GC) compound. It is a potential therapeutic for treating immune mediated disorders. … GC is a glycolipid that has been shown by Enzo scientists and collaborators to act as an anti-inflammatory agent in animal model systems, and therefore is being evaluated as an important candidate

  3. Drug

    Lomerizine

    go.drugbank.com/drugs/DB14065
    Experimental

    Lomerizine is a diphenylmethylpiperazine calcium channel blocker[A245378, A245383] with relatively selective central nervous system (CNS) effects. … [A245383] This drug is used to prophylactically treat migraines[A245368, A245373] and is also being investigated against eye-related diseases that are associated with local circulatory disturbances, an

    Categories: P-glycoprotein inhibitors, Cytochrome P-450 Substrates
  4. Drug

    Maduramicin

    go.drugbank.com/drugs/DB11525
    ExperimentalVet approved

    It is a naturally occurring compound which was first isolated from the actinomycete, Actinomadura rubra. … Maduramicin is an antiprotozoal agent used in veterinary medicine as prophylaxis against coccidiosis.

  5. Drug

    Utidelone

    go.drugbank.com/drugs/DB17575
    Investigational

    Utidelone (UTD1), a novel microtubule stabilizing agent, is an epothilone B analogue produced by genetic engineering.[A257544,A257549] It is under investigation in clinical trials for various cancers.

  6. Drug

    RLYB212

    go.drugbank.com/drugs/DB17727
    Investigational

    RLYB212 is a human monoclonal antibody against Antigen-1A Immunoglobulin (HPA-1A). It is currently being developed by Rallybio for the prevention of fetal and neonatal alloimmune thrombocytopenia.

  7. Drug

    SAR-439459

    go.drugbank.com/drugs/DB17864
    Investigational

    SAR-439459 is a pan-transforming Growth Factor-beta (TGFβ) neutralizing antibody.[A259862] Developed by Sanofi, it is being investigated for the treatment of cancers and Osteogenesis Imperfecta.

  8. Drug

    Efdoralprin alfa

    go.drugbank.com/drugs/DB18384
    Investigational

    Efdoralprin alfa is a recombinant human alpha-1 antitrypsin (AAT)-Fc fusion protein.[L54928] It is being investigated as a restorative therapy in adults with AATD emphysema.[L54928]

  9. Drug

    AB-201

    go.drugbank.com/drugs/DB18629
    Investigational

    AB-201 is a CAR-NK cell therapy targeted against HER2.[L48340] It is under investigation for the treatment of HER2-positive cancers, including breast and gastric carcinomas.

    Synonyms: Ex vivo expanded allogeneic cord blood-derived NK cells that have been genetically modified to express a HER2-directed CAR and secrete IL-15
  10. Drug

    Reloxaliase

    go.drugbank.com/drugs/DB15560
    Investigational

    Reloxaliase is a crystalline formulation of oxalate decarboxylase derived from _Bacillus Subtilis_. … Reloxaliase is under investigation in clinical trial NCT03456830 (Evaluate ALLN-177 in Patients With Enteric Hyperoxaluria).